Interview with Marco Cartolari, CEO, Scharper
Scharper’s history in the Italian market begins in 1958, but the company as we see it today was really created in the mid nineties, when you founded La Farmochimica Italiana…
Address: Viale Ortles, 12 – 20139 Milan (MI),Italy
Tel: +39.02.2629161
Web: http://www.scharper.it/introscharper.htm
Created in 1995 by Dr. Lino Cartolari as La Farmochimica Italiana Srl (LFI), the company then purchased Scharper trademark in 1996 and signs several licensing agreements with different pharma leaders.
Scharper now operates in selected therapeutic areas, and focuses on high profile prescription drugs
(primarily through in-licensing arrangements) as well as highly researched and clinically supported medical foods, nutraceuticals, cosmeceuticals and medical devices( to date developed primarily internally).
Scharper’s focus is unique in that it treats non-drug products with the same scientific scrutiny and rigour as drug products.
Scharper’s history in the Italian market begins in 1958, but the company as we see it today was really created in the mid nineties, when you founded La Farmochimica Italiana…
The CEO of MSD Italy discusses the company’s promising pipeline, its plans to realize growth through the launch of innovative new drugs in 2016, the paths towards a sustainable healthcare…
The MD of the Spanish Chamber of Commerce in Italy takes stock of the prevailing business winds between the two countries as both economies complete their emergence from the shadow of…
Massimo Visentin, Country Leader for Pfizer Italy, discusses the company’s remarkable success in 2015, his hopes and ambitions for the new year, and the need of the industry and Pfizer…
Prof. Luigi Naldini, Director of TIGET, discusses the success of the institute and the groundbreaking partnerships it has formed with the pharmaceutical industry, as well as his ambitions for TIGET…
Pasquale Frega, General Manager for Celgene Italy, discusses the company’s rapid growth and imminent entry into immunology, the business and regulatory environment for innovators in the country and the characteristics…
Dr. Costas Piliounis discusses the importance of containing diabetes, the dampening effects budget ceilings have on companies’ performance and growth potential, as well as the positive influence which changes currently…
Chris Juliam, Managing Director for Takeda Italy, shares the strategy the company is pursuing in the country, the effects market-access issues are having on innovators and patients, and what new…
Prof. Manuela Battaglia (MB) and Prof. Lorenzo Piemonti (LP) discuss the positioning of the Diabetes Research Institute (DRI) within the San Raffaele Scientific Institute and the global diabetes care community,…
Fabrizio Greco, General Manager at AbbVie Italy, discusses the successful launch of the company’s new Hepatitis C treatment, how AbbVie is seeking to position itself as a partner to the…
Enrique Hausermann, CEO of EG, the Stada Group’s Italian affiliate for its generics business, discusses the progress the company has made since 2009, the promising areas for growth he sees…
CFCII’s Director provides us with an overview of the services offered to French and Italian companies by the Chamber, as well as her perceptions about investments between the two countries,…
Alberto Gugliemo, President of the Carlo Besta Institute in Milan, shares the changing perception of neurological diseases and neurological science in Italy, the nature of the institute’s collaboration with the…
See our Cookie Privacy Policy Here